Article By:
The Life Sciences Report
Wednesday, September 9, 2015 5:45 PM EDT
Alan Leong, senior analyst with BioWatch, tells us about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies.
In this article: SRNE, DNDN, MDVN, SGEN, CELG, GILD, REPCF, JUNO, ADXS, KITE, BLUE, XON, CPXX, BLCM, NK